FDA Says Shortage of GLP-1 Tirzepatide Is Over (Gastroenterology Advisor)

The FDA has reaffirmed its decision that the shortage of tirzepatide—marketed as Mounjaro (diabetes) and Zepbound (weight loss)—is officially over. This announcement ends compounding pharmacies’ ability to produce versions of the drug, effective within 60-90 days.